Wednesday 28 October 2009

Precortalon aquosum




Precortalon aquosum may be available in the countries listed below.


Ingredient matches for Precortalon aquosum



Prednisolone

Prednisolone 21-(sodium succinate) (a derivative of Prednisolone) is reported as an ingredient of Precortalon aquosum in the following countries:


  • Sweden

International Drug Name Search

Tuesday 27 October 2009

Digibar 190 oral and rectal


Generic Name: barium sulfate (oral and rectal) (BER ee um SUL fate)

Brand Names: Anatrast, Bar-Test, Baricon, Baro-Cat, Barosperse, Bear-E-Yum GI, CheeTah, CheeTah Butterscotch, CheeTah Chocolaty-Fudge, CheeTah Orange, CheeTah Raspberry, Digibar 190, E-Z AC, E-Z Disk, E-Z Dose Kit with Polibar Plus, E-Z Paste, E-Z-Cat, E-Z-Cat Dry, E-Z-HD, E-Z-Paque, Enecat, Eneset 2, Enhancer, Entero VU, Entero-H, Entrobar, Esopho-Cat, Intropaste, Liqui-Coat HD, Liquid Barosperse, Liquid E-Z Paque, Liquid Polibar, Liquid Polibar Plus, Maxibar, Medebar Plus, Medebar Super 250, Polibar ACB, Readi-Cat, Readi-Cat 2, Scan C, Sitzmarks, Smoothie Readi-Cat 2, Sol-O-Pake, Tagitol V, Tonojug, Tonopaque, Varibar Honey, Varibar Nectar, Varibar Pudding, Varibar Thin, Varibar Thin Honey, Volumen


What is barium sulfate?

Barium sulfate is in a group of drugs called contrast agents. Barium sulfate works by coating the inside of your esophagus, stomach, or intestines which allows them to be seen more clearly on a CT scan or other radiologic (x-ray) examination.


Barium sulfate is used to help diagnose certain disorders of the esophagus, stomach, or intestines.


Barium sulfate may also be used for purposes not listed in this medication guide.


What is the most important information I should know about barium sulfate?


You should not use this medication if you are allergic to barium sulfate. Tell your doctor if you have ever had an allergic reaction to a contrast agent.

Before you use barium sulfate, tell your doctor if you have any allergies, or if you have asthma, cystic fibrosis, heart disease or high blood pressure, rectal cancer, a colostomy, a blockage in your stomach or intestines, a condition called pseudotumor cerebri, or if you have recently had a rectal biopsy or surgery on your esophagus, stomach, or intestines.


Tell your doctor if you are pregnant or breast-feeding before your medical test.

Carefully follow your doctor's instructions about what to eat or drink within the 24-hour period before your test.


Serious side effects of barium sulfate may include severe stomach pain, sweating, ringing in your ears, pale skin, weakness, or severe cramping, diarrhea, or constipation

What should I discuss with my health care provider before using barium sulfate?


You should not use barium sulfate if you are allergic to it. Tell your doctor if you have ever had an allergic reaction to a contrast agent.

To make sure you can safely use barium sulfate, tell your doctor if you have any of these other conditions:



  • asthma, eczema, or allergies;




  • a blockage in your stomach or intestines;




  • cystic fibrosis;




  • a colostomy;




  • rectal cancer;




  • heart disease or high blood pressure;




  • Hirschsprung's disease (a disorder of the intestines);




  • a condition called pseudotumor cerebri (high pressure inside the skull that may cause headaches, vision loss, or other symptoms);




  • a recent history of surgery on your esophagus, stomach, or intestines;




  • a history of perforation (a hole or tear) in your esophagus, stomach, or intestines;




  • if you have recently had a rectal biopsy;




  • if you have ever choked on food by accidentally inhaling it into your lungs;




  • if you are allergic to simethicone (Gas-X, Phazyme, and others); or




  • if you are allergic to latex rubber.




It is not known whether barium sulfate will harm an unborn baby, but the radiation used in x-rays and CT scans may be harmful. Before your medical test, tell your doctor if you are pregnant. Barium sulfate may pass into breast milk and could harm a nursing baby. Before your medical test, tell your doctor if you are breast-feeding a baby.

How should I use barium sulfate?


Use this medication exactly as prescribed by your doctor. Do not use it in larger amounts or for longer than recommended.


Barium sulfate comes in tablets, paste, cream, or liquid forms.


In some cases, barium sulfate is taken by mouth. The liquid form may also be used as a rectal enema.


You may need to begin using this medication at home a day before your medical test. Follow your doctor's instructions about how much of the medication to use and how often.


If you are receiving barium sulfate as a rectal enema, a healthcare professional will give you the medication at the clinic or hospital where your testing will take place.


Do not crush, chew, or break a barium sulfate tablet. Swallow the pill whole.

Dissolve the barium sulfate powder in a small amount of water. Stir this mixture and drink all of it right away. To make sure you get the entire dose, add a little more water to the same glass, swirl gently and drink right away.


If you receive the medication as a liquid to take by mouth, shake the liquid well just before you measure a dose. To be sure you get the correct dose, measure the liquid with a marked measuring spoon or medicine cup, not with a regular table spoon. If you do not have a dose-measuring device, ask your pharmacist for one.

Carefully follow your doctor's instructions about what to eat or drink within the 24-hour period before your test.


Store at room temperature away from heat and moisture. Keep the bottle tightly closed when not in use.

What happens if I miss a dose?


If you are using barium sulfate at home, call your doctor for instructions if you miss a dose.


What happens if I overdose?


Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

Overdose symptoms may include severe stomach pain, ongoing diarrhea, confusion, or weakness.


What should I avoid before or after using barium sulfate?


Follow your doctor's instructions about any restrictions on food, beverages, or activity.


Barium sulfate side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Call your doctor at once if you have a serious side effect such as:

  • severe stomach pain;




  • severe cramping, diarrhea, or constipation;




  • sweating;




  • ringing in your ears;




  • confusion, fast heart rate; or




  • pale skin, weakness.



Less serious side effects may include:



  • mild stomach cramps;




  • nausea, vomiting;




  • loose stools or mild constipation.



This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


What other drugs will affect barium sulfate?


There may be other drugs that can interact with barium sulfate. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.



More Digibar 190 resources


  • Digibar 190 Side Effects (in more detail)
  • Digibar 190 Use in Pregnancy & Breastfeeding
  • 0 Reviews for Digibar90 - Add your own review/rating


Compare Digibar 190 with other medications


  • Computed Tomography


Where can I get more information?


  • Your doctor or pharmacist can provide more information about barium sulfate.

See also: Digibar90 side effects (in more detail)


Thursday 22 October 2009

Paroxétine Ratiopharm




Paroxétine Ratiopharm may be available in the countries listed below.


Ingredient matches for Paroxétine Ratiopharm



Paroxetine

Paroxetine hydrochloride (a derivative of Paroxetine) is reported as an ingredient of Paroxétine Ratiopharm in the following countries:


  • France

International Drug Name Search

Wednesday 21 October 2009

Brevital Sodium


Pronunciation: meth-oh-HEX-ih-tahl
Generic Name: Methohexital
Brand Name: Brevital Sodium

Brevital Sodium should only be used in a hospital or clinical setting that provide for continuous monitoring of your breathing and heart functions.





Brevital Sodium is used for:

Inducing anesthesia (lack of sensation or feeling) prior to surgical procedures in adults and children older than 1 month of age. It may also be used to induce sleep. Brevital Sodium may be used alone or in combination with other medicines.


Brevital Sodium is a barbiturate anesthetic. It works by depressing the activity of the brain to inhibit painful sensations and inducing sleep.


Do NOT use Brevital Sodium if:


  • you are allergic to any ingredient in Brevital Sodium

  • you have the blood disease porphyria or are unable to receive anesthesia

  • you are taking sodium oxybate (GHB)

Contact your doctor or health care provider right away if any of these apply to you.



Before using Brevital Sodium:


Some medical conditions may interact with Brevital Sodium. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you have depression, severe liver or heart problems, lung disease, blood circulation problems, breathing problems, asthma (especially severe asthma requiring hospitalization), high or low blood pressure, heart disease or failure, severe anemia, kidney problems, or an endocrine disorder

  • if you have suicidal thoughts or behaviors, are in a weakened state or shock, or have a history of seizures

  • if you abuse or are dependent on drugs

Some MEDICINES MAY INTERACT with Brevital Sodium. Tell your health care provider if you are taking any other medicines, especially any of the following:


  • Amiodarone, droxidopa, ethanol, narcotic analgesics (eg, codeine), or sodium oxybate (GHB) because the risk of serious side effects may be increased

  • Barbiturates or phenytoin because the effectiveness of Brevital Sodium may be decreased

This may not be a complete list of all interactions that may occur. Ask your health care provider if Brevital Sodium may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Brevital Sodium:


Use Brevital Sodium as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Brevital Sodium is usually administered as an injection at your doctor's office, hospital, or clinic. If you are using Brevital Sodium at home, carefully follow the injection procedures taught to you by your health care provider.

  • If Brevital Sodium contains particles or is discolored, or if the vial is cracked or damaged in any way, do not use it.

  • It is best to use Brevital Sodium on an empty stomach.

  • Keep this product, as well as syringes and needles, out of the reach of children and away from pets. Do not reuse needles, syringes, or other materials. Dispose of properly after use. Ask your doctor or pharmacist to explain local regulations for proper disposal.

  • If you miss a dose of Brevital Sodium, contact your doctor immediately.

Ask your health care provider any questions you may have about how to use Brevital Sodium.



Important safety information:


  • Brevital Sodium may cause drowsiness for up to 12 hours. Do not drive, operate machinery, or do anything else that could be dangerous for at least 12 hours following surgery.

  • Brevital Sodium may cause seizures in patients with a history of seizures, especially partial seizure disorders.

  • If pain, whitening, or discoloration occurs at the injection site, tell your health care provider immediately.

  • Use Brevital Sodium with caution in the ELDERLY because they may be more sensitive to its effects.

  • Use Brevital Sodium with caution in CHILDREN younger than 1 month of age. Safety and effectiveness in this age group have not been confirmed.

  • PREGNANCY and BREAST-FEEDING: If you become pregnant while using Brevital Sodium, discuss with your doctor the benefits and risks of using Brevital Sodium during pregnancy. If you are or will be breast-feeding while you are using Brevital Sodium, check with your doctor or pharmacist to discuss the risks to your baby.


Possible side effects of Brevital Sodium:


All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Anxiety; coughing; drowsiness; flushing; headache; hiccups; itching; muscle twitching; nausea; pain at the injection site; restlessness; salivation; stomach pain; swelling of the veins; vomiting.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); burning or swelling at the injection site; delirium; fast heartbeat; interrupted breathing; seizures; throat spasms.



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.


See also: Brevital Sodium side effects (in more detail)


If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include allergic reactions; breathing problems; coughing; depression; drowsiness; light-headedness; low blood pressure; muscle twitching; seizures; slowed or interrupted breathing; throat problems.


Proper storage of Brevital Sodium:

Brevital Sodium is usually handled and stored by a health care provider. If you are using Brevital Sodium at home, store Brevital Sodium as directed by your pharmacist or health care provider. Keep Brevital Sodium out of the reach of children and away from pets.


General information:


  • If you have any questions about Brevital Sodium, please talk with your doctor, pharmacist, or other health care provider.

  • Brevital Sodium is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Brevital Sodium. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Brevital Sodium resources


  • Brevital Sodium Side Effects (in more detail)
  • Brevital Sodium Use in Pregnancy & Breastfeeding
  • Brevital Sodium Drug Interactions
  • Brevital Sodium Support Group
  • 0 Reviews for Brevital Sodium - Add your own review/rating


  • Brevital Sodium Prescribing Information (FDA)

  • Brevital Sodium Concise Consumer Information (Cerner Multum)



Compare Brevital Sodium with other medications


  • Anesthesia
  • Anesthetic Adjunct

Tuesday 20 October 2009

Procain Röwo




Procain Röwo may be available in the countries listed below.


Ingredient matches for Procain Röwo



Procaine

Procaine hydrochloride (a derivative of Procaine) is reported as an ingredient of Procain Röwo in the following countries:


  • Germany

International Drug Name Search

Aspilet-Thrombo




Aspilet-Thrombo may be available in the countries listed below.


Ingredient matches for Aspilet-Thrombo



Aspirin

Acetylsalicylic Acid is reported as an ingredient of Aspilet-Thrombo in the following countries:


  • Vietnam

International Drug Name Search

Tuesday 13 October 2009

Cabergoline




In some countries, this medicine may only be approved for veterinary use.


In the US, Cabergoline (cabergoline systemic) is a member of the following drug classes: dopaminergic antiparkinsonism agents, prolactin inhibitors and is used to treat Hyperprolactinemia.

US matches:

  • Cabergoline

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

G02CB03,N04BC06

CAS registry number (Chemical Abstracts Service)

0081409-90-7

Chemical Formula

C26-H37-N5-O2

Molecular Weight

451

Therapeutic Category

Prolactin inhibitor

Chemical Name

1-[(6-Allylergolin-8ß-yl)carbonyl]-1-[(3-(dimethylamino)propyl]-3-ethylurea

Foreign Names

  • Cabergolinum (Latin)
  • Cabergolin (German)
  • Cabergoline (French)
  • Cabergolina (Spanish)

Generic Names

  • Cabergolina (OS: DCIT)
  • Cabergoline (OS: USAN, BAN)
  • FCE 21336 (IS: FarmitaliaCarl)
  • Cabergoline (PH: BP 2010, Ph. Eur. 6, USP 32)
  • Cabergolinum (PH: Ph. Eur. 6)

Brand Names

  • Actualene
    Pfizer, Italy


  • Agalates
    Ivax, Russian Federation


  • Cabaser
    Kissei, Japan; Pfizer, Argentina; Pfizer, Australia; Pfizer, Switzerland; Pfizer, Denmark; Pfizer, Finland; Pfizer, United Kingdom; Pfizer, Israel; Pfizer, Italy; Pfizer, Norway; Pfizer, Sweden; Pharmacia, Bulgaria; Pharmacia, Ireland; Pharmacia, Poland; Pharmacia, Serbia


  • Cabaseril
    Pfizer, Austria; Pfizer, Germany


  • CabergoLek
    Lek, Poland


  • Cabergolin AL
    Aliud, Germany


  • Cabergolin beta
    Betapharm, Germany


  • Cabergolin dura
    Mylan dura, Germany


  • Cabergolin Hexal
    Hexal, Germany; Hexal A/S, Denmark


  • Cabergolin Sandoz
    Sandoz, Austria; Sandoz, Germany


  • Cabergolin Stada
    Stada, Germany


  • Cabergolin Teva
    Teva, Denmark; Teva, Malta


  • Cabergolina ratiopharm
    Ratiopharm, Italy


  • Cabergolina Sandoz
    Sandoz, Italy


  • Cabergolina Teva
    Teva, Italy


  • Cabergolina
    Monte, Argentina


  • Cabergolin-CT
    CT Arzneimittel, Germany


  • Cabergoline Arrow
    Arrow, Netherlands


  • Cabergoline Hexal
    Sandoz, Sweden


  • Cabergoline PCH
    Pharmachemie, Netherlands


  • Cabergoline Sandoz
    Sandoz, Netherlands


  • Cabergoline Teva
    Teva, Belgium; Teva Santé, France


  • Cabergoline
    Arrow, Malta; Cobalt, United States; Par, United States; Teva USA, United States; Watson, United States


  • Cabergolin-ratiopharm
    Ratiopharm, Germany


  • Cabergo-Teva
    Teva, Germany


  • Caberlin
    Sun, India; Sun, Myanmar


  • Caberpar
    Rontag, Argentina


  • Cabeser
    Pfizer, Turkey


  • Cabest
    Teva, Slovakia


  • Cieldom
    Teva, Argentina


  • CO Cabergoline
    Cobalt, Canada


  • Dostinex
    Delphi, Netherlands; Dr. Fisher, Netherlands; Euro, Netherlands; Paladin, Canada; Pfizer, Argentina; Pfizer, Austria; Pfizer, Australia; Pfizer, Belgium; Pfizer, Bahrain; Pfizer, Brazil; Pfizer, Switzerland; Pfizer, Chile; Pfizer, Colombia; Pfizer, Costa Rica; Pfizer, Czech Republic; Pfizer, Germany; Pfizer, Ecuador; Pfizer, Spain; Pfizer, Finland; Pfizer, France; Pfizer, United Kingdom; Pfizer, Georgia; Pfizer, Greece; Pfizer, Guatemala; Pfizer, Hong Kong; Pfizer, Honduras; Pfizer, Ireland; Pfizer, Israel; Pfizer, Iceland; Pfizer, Italy; Pfizer, Lithuania; Pfizer, Latvia; Pfizer, Malta; Pfizer, Mexico; Pfizer, Malaysia; Pfizer, Nicaragua; Pfizer, Netherlands; Pfizer, Norway; Pfizer, New Zealand; Pfizer, Oman; Pfizer, Panama; Pfizer, Peru; Pfizer, Poland; Pfizer, Portugal; Pfizer, Romania; Pfizer, Russian Federation; Pfizer, Sweden; Pfizer, Singapore; Pfizer, El Salvador; Pfizer, Tunisia; Pfizer, Turkey; Pfizer, Taiwan; Pfizer, United States; Pfizer, Venezuela; Pfizer, South Africa; Pharmacia, Luxembourg


  • Galastop (veterinary use)
    Biokema, Switzerland; Boehringer Ingelheim Vetmedica, United Kingdom; Ceva, Belgium; Ceva, Germany; Ceva, France; Ceva, Netherlands; Ceva, Portugal; Ceva Vetem, Norway; CEVA Vetpharma, Sweden; Orion, Finland; Richter, Austria; Vetem, Italy


  • Kabergolin IVAX
    Ivax, Sweden


  • Lac Stop
    Rontag, Argentina


  • Lactamax
    Beta, Argentina


  • Lactovet (veterinary use)
    Omega Pharma France, France


  • Prolastat
    Metlen, Colombia


  • Sogilen
    Pfizer, Spain


  • Sostilar
    Pfizer, Belgium; Pharmacia, Luxembourg


  • Triaspar
    Beta, Argentina

International Drug Name Search

Glossary

BANBritish Approved Name
DCITDenominazione Comune Italiana
ISInofficial Synonym
OSOfficial Synonym
PHPharmacopoeia Name
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Dopamin Admeda




Dopamin Admeda may be available in the countries listed below.


Ingredient matches for Dopamin Admeda



Dopamine

Dopamine hydrochloride (a derivative of Dopamine) is reported as an ingredient of Dopamin Admeda in the following countries:


  • Croatia (Hrvatska)

  • Hungary

International Drug Name Search

Sunday 11 October 2009

Xitrocin




Xitrocin may be available in the countries listed below.


Ingredient matches for Xitrocin



Roxithromycin

Roxithromycin is reported as an ingredient of Xitrocin in the following countries:


  • Poland

International Drug Name Search

Doxytrex




Doxytrex may be available in the countries listed below.


Ingredient matches for Doxytrex



Calcium Dobesilate

Calcium Dobesilate is reported as an ingredient of Doxytrex in the following countries:


  • Guatemala

Doxycycline

Doxycycline hyclate (a derivative of Doxycycline) is reported as an ingredient of Doxytrex in the following countries:


  • Portugal

International Drug Name Search

Thursday 8 October 2009

Rapaflo


Rapaflo is a brand name of silodosin, approved by the FDA in the following formulation(s):


RAPAFLO (silodosin - capsule; oral)



  • Manufacturer: WATSON LABS

    Approval date: October 8, 2008

    Strength(s): 4MG, 8MG [RLD]

Has a generic version of Rapaflo been approved?


No. There is currently no therapeutically equivalent version of Rapaflo available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Rapaflo. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • 1,5,7-trisubstituted indoline compounds and salts thereof
    Patent 5,387,603
    Issued: February 7, 1995
    Inventor(s): Kitazawa; Makio & Ban; Masaaki & Okazaki; Kosuke & Ozawa; Motoyasu & Yazaki; Toshikazu & Yamagishi; Ryoichi
    Assignee(s): Kissei Pharmaceutical Co., Ltd.
    Indoline compounds represented by the formula: ##STR1## wherein R represents a saturated or unsaturated aliphatic acyl group which may have one or more halogen atoms, a hydroxy group, a lower alkoxy group, a carboxy group, a lower alkoxycarbonyl group, a cycloalkyl group or an aryl group as substituents; a hydroxyalkyl group; an aliphatic acyloxyalkyl group; a lower alkyl group having a lower alkoxy group, a carboxy group, a lower alkoxycarbonyl group, an aryl substituted lower alkoxycarbonyl group, a carbamoyl group, a mono- or dialkyl substituted carbamoyl group or a cyano group as substituents; an aromatic acyl group which may have one or more halogen atoms as substituents; a furoyl group or a pyridylcarbonyl group; R.sup.1 represents a lower alkyl group which may have one or more halogen atoms or an aryl group as substituents; and pharmaceutically acceptable salts thereof, exhibit a selective suppressive action on urethral contractions, and thus are useful as therapeutic agents for the treatment of dysuria with less hypotension including postural hypotension.
    Patent expiration dates:

    • December 1, 2018
      ✓ 
      Drug substance
      ✓ 
      Drug product




  • Use of .alpha..sub.1C specific compounds to treat benign prostatic hyperlasia
    Patent 5,403,847
    Issued: April 4, 1995
    Inventor(s): Gluchowski; Charles & Forray; Carlos C. & Chiu; George & Branchek; Theresa A. & Wetzel; John M. & Hartig; Paul R.
    Assignee(s): Synaptic Pharmaceutical Corporation
    A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human .alpha..sub.1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human .alpha..sub.1A adrenergic receptor, a human .alpha..sub.1B adrenergic receptor, and a human histamine H.sub.1 receptor, and, binds to a human .alpha..sub.2 adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such .alpha..sub.1C adrenergic receptor. Compounds meeting these criteria are provided.
    Patent expiration dates:

    • November 13, 2012
      ✓ 
      Patent use: USE IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)




  • Use of .alpha..sub.1c specific compounds to treat benign prostatic hyperplasia
    Patent 5,780,485
    Issued: July 14, 1998
    Inventor(s): Gluchowski; Charles & Forray; Carlos C. & Chiu; George & Branchek; Theresa A. & Wetzel; John M. & Hartig; Paul R.
    Assignee(s): Synaptic Pharmaceutical Corporation
    A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human .alpha..sub.1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human .alpha..sub.1A adrenergic receptor, a human .alpha..sub.1B adrenergic receptor, and a human histamine H.sub.1 receptor, and, binds to a human .alpha..sub.2 adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such .alpha..sub.1C adrenergic receptor. Compounds meeting these criteria are provided.
    Patent expiration dates:

    • November 13, 2012
      ✓ 
      Patent use: USE IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)




  • Use of alpha-1C specific compounds to treat benign prostatic hyperplasia
    Patent 6,015,819
    Issued: January 18, 2000
    Inventor(s): Gluchowski; Charles & Forray; Carlos C. & Chiu; George & Branchek; Theresa A. & Wetzel; John M. & Hartig; Paul R.
    Assignee(s): Synaptic Pharmaceutical Corporation
    A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human .alpha..sub.1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human .alpha..sub.1A adrenergic receptor, a human .alpha..sub.1B adrenergic receptor, and a human histamine H.sub.1 receptor, and, binds to a human .alpha..sub.2 adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such .alpha..sub.1C adrenergic receptor. Compounds meeting these criteria are provided.
    Patent expiration dates:

    • November 13, 2012
      ✓ 
      Patent use: USE IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)



Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • October 8, 2013 - NEW CHEMICAL ENTITY

See also...

  • Rapaflo Consumer Information (Drugs.com)
  • Rapaflo Consumer Information (Wolters Kluwer)
  • Rapaflo Consumer Information (Cerner Multum)
  • Rapaflo Advanced Consumer Information (Micromedex)
  • Rapaflo AHFS DI Monographs (ASHP)
  • Silodosin Consumer Information (Wolters Kluwer)
  • Silodosin Consumer Information (Cerner Multum)
  • Silodosin Advanced Consumer Information (Micromedex)
  • Silodosin AHFS DI Monographs (ASHP)

Glucar




Glucar may be available in the countries listed below.


Ingredient matches for Glucar



Acarbose

Acarbose is reported as an ingredient of Glucar in the following countries:


  • Sri Lanka

International Drug Name Search

Wednesday 7 October 2009

Insulin Humalog Humaject




Insulin Humalog Humaject may be available in the countries listed below.


Ingredient matches for Insulin Humalog Humaject



Insulin Lispro

Insulin Lispro is reported as an ingredient of Insulin Humalog Humaject in the following countries:


  • Luxembourg

International Drug Name Search

Benazepril STADA




Benazepril STADA may be available in the countries listed below.


Ingredient matches for Benazepril STADA



Benazepril

Benazepril hydrochloride (a derivative of Benazepril) is reported as an ingredient of Benazepril STADA in the following countries:


  • Poland

International Drug Name Search

Tuesday 6 October 2009

Xynor




Xynor may be available in the countries listed below.


Ingredient matches for Xynor



Ornidazole

Ornidazole is reported as an ingredient of Xynor in the following countries:


  • Bangladesh

International Drug Name Search

Monday 5 October 2009

Docosanol




Scheme

USAN

ATC (Anatomical Therapeutic Chemical Classification)

D06BB11

CAS registry number (Chemical Abstracts Service)

0000661-19-8

Chemical Formula

C22-H46-O

Molecular Weight

326

Therapeutic Category

Antiviral agent

Chemical Names

1-Docosanol (USAN)

n-Docosanol (IUPAC)

Foreign Names

  • Docosanol (German)
  • Docosanol (French)

Generic Names

  • Docosanol (OS: DCF, USAN)
  • Behenic alcohol (IS)
  • Behenyl alcohol (IS: INCI)
  • Docosan-1-ol (IS: ASK)
  • Docosyl alcohol (IS)
  • IK-2 (IS)
  • Lanette 22 (IS)

Brand Names

  • Abrax
    CTS, Israel


  • Abreva
    GlaxoSmithKline, United States; GlaxoSmithKline Consumer Healthcare, Canada


  • Erazaban
    Healthcare, Slovenia; Healthcare Brands, Latvia; Healthcare Brands International, Slovakia


  • Healip
    Aco Hud, Finland; Jenson, Greece; Jenson Pharmaceutical Services, Denmark


  • Heloc
    Jenson, Norway


  • Herepair
    Boryung, South Korea


  • Lafrost
    Incepta, Bangladesh


  • Pigenil
    Pharmafar, Italy

International Drug Name Search

Glossary

DCFDénomination Commune Française
IUPACInternational Union of Pure and Applied Chemistry
ISInofficial Synonym
OSOfficial Synonym
USANUnited States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Isotenk




Isotenk may be available in the countries listed below.


Ingredient matches for Isotenk



Isoxsuprine

Isoxsuprine hydrochloride (a derivative of Isoxsuprine) is reported as an ingredient of Isotenk in the following countries:


  • Argentina

International Drug Name Search